Genomed Spólka Akcyjna (WSE:GEN)

Market Cap	37.79M -3.4%
Revenue (ttm)	27.49M +19.2%
Net Income	3.27M +272.9%
EPS	2.48 +272.9%
Shares Out	1.32M
PE Ratio	11.55
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9
Average Volume	22
Open	28.20
Previous Close	n/a
Day's Range	27.80 - 28.20
52-Week Range	23.00 - 30.60
Beta	-0.10
RSI	48.45
Earnings Date	Feb 13, 2026

About Genomed Spólka Akcyjna

Genomed Spólka Akcyjna provides DNA sequencing and analysis and diagnostics services for congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company’s diagnostic services include DNA isolation, PCR amplification of chosen DNA regions, comparison of the sequences, and interpretation of the results by diagnosticians. It also provides various types of DNA sequence analysis, including polymorphism analysis or sequencing ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2007
• Employees: 53
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: GEN

Financial Performance

In 2024, Genomed Spólka Akcyjna's revenue was 23.01 million, an increase of 2.34% compared to the previous year's 22.48 million. Earnings were 1.11 million, an increase of 19.32%.